alzheimer's%20disease%20-and-%20dementia
ALZHEIMER'S DISEASE AND DEMENTIA
Dementia is a clinical syndrome characterized by impairment of multiple higher cortical functions that include memory, orientation, thinking, comprehension, calculation, capacity for learning, language, judgment,  executive function and visuo-spatial function. It is usually accompanied or preceded by deterioration in emotional control, social behavior or motivation.
Alzheimer's disease is the most common cause of dementia. Sporadic cases usually present after >60 year while familial types are rare and present in <60 year of age (early-onset dementia).
Short-term memory loss is the most common early symptom. Other spheres of cognitive impairment manifest after several years.
  1. Alvarez XA, Cacabelos R, Sampedro C, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol. 2010;18(1):59-68. doi: 10.1111/j.1468-1331.2010.03092.x. Accessed 15 Mar 2011. PMID: 20500802
  2. American Psychiatric Association. Practice guidelines for the treatment of patients with Alzheimer’s disease and other dementias of late life. Am J Psychiatry. 1997 May;154(Suppl 5):001-39. PMID: 9140238
  3. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007 Jul;69(5):459-469. PMID: 17664405
  4. Bain LJ. A review of the "State of the Art" on mild cognitive impairment: the fourth annual symposium. Alzheimers Dement. 2006 Jul;2(3):246-256. PMID: 19595894
  5. Corey-Bloom J. Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int J Clin Pract. 2003 Apr;57(3):219-223. PMID: 12723727
  6. Delagarza VW. Pharmacologic treatment of Alzheimer's disease: an update. Am Fam Physician. 2003 Oct;68(7):1365-1372. PMID: 14567491
  7. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry. 2003 Mar;11(2):131-145. PMID: 12611743
  8. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May;56(9):1154-1166. PMID: 11342679
  9. Douglas S, James I, Ballard C. Non-pharmacological interventions in dementia. Adv Psychiatr Treat. 2004;10:171-179
  10. Farlow MR, Small GW, Quarg P, Krause A. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. Dement Geriatr Cogn Disord. 2005;20:192-197. PMID: 16088144
  11. Erkinjuntti T, Kurz A, Small GW, et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther. 2003 Jun;25(6):1765-1782. PMID: 12860497
  12. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002 Apr;359(9314):1283-1290. PMID: 11965273
  13. Gauthier S, Herrmann N, Ferreri F, et al. Use of memantine to treat Alzheimer's disease. CMAJ. 2006 Aug;175(5):501-502. PMID: 16940271
  14. Hort J, O’Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol. 2010 Oct;17(10):1236-1248. doi: 10.111/j.1468-1331.2010.03040.x. PMID: 20831773
  15. Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2003(1)
  16. Ihl R, Bachinskaya N, Korczyn A, et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry. 2010 Nov;26(11):1186-1194. doi: 10.1002/gps.2662. PMID: 21140383
  17. Ihl R, Frolich L, Winblad B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. World J Biol Psychiatry. 2011 Feb;12(1):002-32. PMID: 21288069
  18. Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2000;4:CD002854. doi: 10.1002/14651858.CD002854. PMID: 11034775
  19. Lanctot KL, Hermann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ. 2003 Sep;169(6):557-564. PMID: 12975222
  20. Kasper S, Schubert H. Ginkgo biloba extract EGb 761 in the treatment of dementia: evidence of efficacy and tolerability. Fortschr Neurol Psychiatr. 2009 Sep;77(9):494-506. doi: 10.1055/s-0028-1109504. Accessed 04 Apr 2011. PMID: 19621278
  21. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May;56(9):1143-1153. PMID: 11342678
  22. Lippa CF, Duda JE, Grossman H, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007 Mar;68(11):812-819. PMID: 17353469
  23. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med. 1999 Nov;341(22):1670-1679. PMID: 10572156
  24. Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May;56(9):1133-1142. PMID: 11342677
  25. Roman GC. Rivastigmine for subcortical vascular dementia. Expert Rev Neurother. 2005 May;5(3):309-313. PMID: 15938663
  26. Wei ZH, He QB, Wang H, et al. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease [abstract]. J Neural Transm. 2007;114(5):629-634. http://www.ncbi.nlm.nih.gov. Accessed 15 Mar 2011. PMID: 17318304
  27. Plosker GL, Gauthier S. Cerebrolysin: A review of its use in dementia [abstract]. Drugs & Aging. 2009 Nov;26(11):893-915. doi: 10.2165/11203320-000000000-00000. Accessed 15 Mar 2011. PMID: 19848437
  28. Ubhi K, Rockenstein E, Doppler E, et al. Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin. Acta Neuropathol. 2009 Jun;117(6):699-712. PMID: 19252918
  29. Weinmann S, Roll S, Schwarzbach C, et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010 Mar;10(14):001-12. http://www.biomedcentral.com. Accessed 04 Apr 2011. PMID: 20236541
  30. MedWormhttp://www.medworm.com/rss/index.php/Neurology/25/http://www.medworm.com/rss/medicalfeeds/specialities/Neurology.xml
  31. MedWorm http://www.medworm.com/rss/index.php/Psychiatry/172/ www.medworm.com/rss/medicalfeeds/specialities/Psychiatry-News.xml
  32. Kuljis R. Alzheimer disease. eMedicine. http://emedicine.medscape.com. 2007.
  33. Ministry of Health Singapore. Clinical practice guidelines: dementia. MOH (Singapore). http://www.moh.gov.sg. 2007. Accessed 15 Mar 2011.
  34. Academy of Medicine of Malaysia, Ministry of Health of Malaysia. Clinical practice guidelines for management of dementia. Academy of Medicine of Malaysia. http://www.acadmed.org.my. Jun 2003.
  35. National Collaborating Centre for Mental Health. Dementia: supporting people with dementia and their carers in health and social care. National Clinical Practice guideline No. 42. NICE. http://www.nice.org.uk. 2007. Accessed 15 Mar 2011.
  36. National Institute for Health and Care Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease. Review of NICE technology appraisal guidance 111. NICE. http://www.nice.org.uk. Sep 2007.
  37. National Collaborating Centre for Mental Health. Dementia: supporting people with dementia and their carers in health and social care. National Clinical Practice guideline No. 42. NICE. http://www.nice.org.uk. 2011. Accessed 05 Apr 2011.
  38. American Psychiatric Association. Guideline watch: practice guidelines for the treatment of patients with Alzheimer’s disease and other dementias of late life. Psychiatryonline. www.psychiatryonline.org. Apr 2006
  39. Fisher Center for Alzheimer’s Research Foundation. New concerns raised about vitamin E and Alzheimer’s. http://www.alzinfo.org. 29 Nov 2004.
  40. Scottish Intercollegiate Guidelines Network. Management of patients with dementia: national clinical guideline. SIGN. http://www.sign.ac.uk. Feb 2006.
  41. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias [2nd ed]. Psychiatryonline. http://www.psychiatryonline.com. Oct 2007. Accessed 15 Mar 2011.
  42. Rabins P, Rovner B, Rummans T, et al. Guideline watch (October 2014): practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Psychiatryonline. http://psychiatryonline.org. Oct 2014. Accessed 18 Aug 2015.
  43. The Hong Kong Geriatrics Society. Treatment guideline and practical tips in using cholinesterase inhibitors and NMDA receptor antagonist. In: Wai AYT. Practical manual of neurocognitive disorders in older adults; 2014 Jun:162-167.
  44. Prince M, Wilmo A, Guerchet M, et al. World Alzheimer Report 2015 - the global Impact of dementia: an analysis of prevalence, incidence, cost and trends. . Alzheimer’s Disease International. http://www.alz.co.uk. 2015.
  45. Keene CD, Montine TJ, Kuller LH. Epidemiology, pathology and pathogenesis of Alzheimer disease. UpToDate. https://www.uptodate.com. Jan 2018. Accessed 26 Apr 2017.
  46. World Health Organization. Risk reduction of cognitive decline and dementia: WHO guidelines. WHO. http://www.who.int. 2019.
  47. Farlow MR. Clinical features and diagnosis of dementia with Lewy bodies. UpToDate. http://www.uptodate.com. Aug 2017.
  48. Larson EB. Evaluation of cognitive impairment and dementia. UpToDate. http://www.uptodate.com. May 2019.
  49. Press D, Alexander M. Treatment of dementia. UpToDate. http://www.uptodate.com. Jan 2018.
  50. Press D, Alexander M. Management of neuropsychiatric symptoms of dementia. UpToDate. http://www.uptodate.com. Nov 2018. Accessed 10 Jun 2019.
  51. Wolk DA, Dickerson BC. Clinical features and diagnosis of Alzheimer disease. UpToDate. http://www.uptodate.com. Nov 2018.
  52. Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Jan;90(3):126-135. doi: 10.1212/WNL.0000000000004826. PMID: 29282327
  53. Academy of Medicine Malaysia, Ministry of Health Malaysia. Management of dementia (2nd edition). http://www.acadmed.org.my. 2009. Accessed 10 Jun 2019.
  54. Cognitive Decline Partnership Centre. Clinical practice guidelines and principles of care for people with dementia. Australian Clinical Practice Guidelines. http://www.clinicalguidelines.gov.au. 2016.
  55. Epperly T, Dunay MA, Boice JL. Alzheimer disease: Pharmacologic and nonpharmacologic therapies for cognitive and functional symptoms. Am Fam Physician. 2017 Jun;95(12):771-778. PMID: 28671413
  56. Farlow MR, Small GW, Quarg P, et al. Efficacy of rivastigmine in alzheimer’s disease patients with rapid disease progression: Results of a meta-analysis. Dement Geriatr Cogn Disord. 2005;20(2-3):192-197. doi: 10.1159/000087301. PMID: 16088144
  57. Larson EB. Risk factors for cognitive decline and dementia. UpToDate. http://www.uptodate.com. Dec 2017. Accessed 10 Jun 2019.
  58. Lorentz WJ, Scanlan JM, Borson S. Brief screening tests for dementia. Can J Psychiatry. 2002 Oct;47(8):723-733. doi: 10.1177/070674370204700803. PMID: 12420650
  59. Ministry of Health Singapore. Dementia: MOH clinical practice guidelines 1/2013. http://www. moh.gov.sg. Apr 2013.
  60. National Institute for Health and Care Excellence (NICE). Donezepil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease NICE technology appraisal guidance 217. NICE. http://www.nice.org.uk. Mar 2011.
  61. Peterson R, Graff-Radford J. Alzheimer disease and other dementias. In: Daroff RB, Jankovic J, Mazziotta JC, et al. Bradley's Neurology in Clinical Practice. 7th ed. Philadelphia, Pennsylvania, USA: Saunders, Elsevier; 2016. http://dx.doi.org/10.1016/B978-0-323-28783-8.00095-8. :1380-1421.
  62. Press D, Alexander M. Cholinesterase inhibitors in the treatment of dementia. UpToDate. http://www.uptodate.com. Mar 2018.
  63. Qui C, Kivipelto M, von Strauss E. Epidemiology of alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111-128. PMID: 19585947
  64. Reese TR, Thiel DJ, Cocker KE. Behavioral disorders in dementia: appropriate nondrug interventions and antipsychotic use. Am Fam Physician. 2016 Aug;94(4):276-282. PMID: 27548592
  65. Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016 May;173(5):543-546. doi: 10.1176/appi.ajp.2015.173501. PMID: 27133416
  66. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012 Sep;19(9):1159-1179. doi: 10.1111/j.1468-1331.2012.03784.x. PMID: 22891773
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, Yesterday

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
5 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.